Mononuclear phagocytes in head and neck squamous cell carcinoma

European Archives of Oto-Rhino-Laryngology

Volumn 267, Issue 3, 2010, Pages 335-344

  Kross, Kenneth Wilfried ^a   Heimdal, John Helge ^b   Aarstad, Hans Jørgen ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Haukeland University   (Norway)

Author keywords

Fragment spheroids; Head and neck squamous cell carcinoma; Innate immune system; Interleukin 6; Macrophages; Monocytes; Mononuclear phagocytes

Indexed keywords

ATIPRIMOD; BORTEZOMIB; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PICIBANIL; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; STEROID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE SYSTEM; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LUNG NON SMALL CELL CANCER; MACROPHAGE; MONONUCLEAR PHAGOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MACROPHAGES; MONOCYTES; MONONUCLEAR PHAGOCYTE SYSTEM; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PHAGOCYTOSIS; PICIBANIL; PROGNOSIS; TUMOR BURDEN;

EID: 77949269481     PISSN: 09374477     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00405-009-1153-y     Document Type: Review

References (107)

1. A Jemal R Siegel E Ward, et al. 2006 Cancer statistics CA Cancer J Clin 56 2 106 130 16514137
2. S Marur AA Forastiere 2008 Head and neck cancer: changing epidemiology, diagnosis, and treatment Mayo Clin Proc 83 4 489 501 18380996
3. WI Wei 2002 Commentary: head and neck carcinomas in the developing world BMJ 325 7368 827 12378727
4. N Johnson 2001 Tobacco use and oral cancer: a global perspective J Dent Educ 65 4 328 339 1:STN:280:DC%2BD3M3nt1alug%3D%3D 11336118
5. S McMahon AY Chen 2003 Head and neck cancer Cancer Metastasis Rev 22 1 21 24 1:CAS:528:DC%2BD3sXpt1Wktg%3D%3D 12716033
6. A Forastiere W Koch A Trotti D Sidransky 2001 Head and neck cancer N Engl J Med 345 26 1890 1900 1:STN:280:DC%2BD38%2FlvFektA%3D%3D 11756581
7. B Brockstein DJ Haraf AW Rademaker, et al. 2004 Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience Ann Oncol 15 8 1179 1186 1:STN:280: DC%2BD2cznt1WmsQ%3D%3D 15277256
8. JP Pignon J Bourhis C Domenge L Designe 2000 Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer Lancet 355 9208 949 955 1:STN:280:DC%2BD3c3ivV2iuw%3D%3D 10768432
9. JS Cooper TF Pajak AA Forastiere, et al. 2004 Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 19 1937 1944 15128893
10. ES Kim M Kies RS Herbst 2002 Novel therapeutics for head and neck cancer Curr Opin Oncol 14 3 334 342 1:CAS:528:DC%2BD38XktlWgsLc%3D 11981281
11. TY Seiwert EE Cohen 2005 State-of-the-art management of locally advanced head and neck cancer Br J Cancer 92 8 1341 1348 1:CAS:528:DC%2BD2MXjsVSjsb0%3D 15846296
12. JA Bonner PM Harari J Giralt, et al. 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 567 578 1:CAS:528:DC%2BD28Xhtleksbs%3D 16467544
13. NW Choong EE Cohen 2006 Epidermal growth factor receptor directed therapy in head and neck cancer Crit Rev Oncol Hematol 57 1 25 43 16207530
14. KE de Visser LV Korets LM Coussens 2005 De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent Cancer Cell 7 5 411 423 15894262
15. JA Van Ginderachter K Movahedi G Hassanzadeh Ghassabeh, et al. 2006 Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion Immunobiology 211 6-8 487 501 16920488
16. M Okamoto G Ohe T Oshikawa, et al. 2000 Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent Immunopharmacology 49 3 363 376 1:CAS:528:DC%2BD3cXmtlGltbY%3D 10996034
17. J Baran M Baj-Krzyworzeka K Weglarczyk I Ruggiero M Zembala 2004 Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae Cancer Immunol Immunother 53 12 1127 1134 1:CAS:528:DC%2BD2cXotlKgtrc%3D 15696610
18. VE Ooi F Liu 2000 Immunomodulation and anti-cancer activity of polysaccharide-protein complexes Curr Med Chem 7 7 715 729 1:CAS:528: DC%2BD3cXjvFCmtLY%3D 10702635
19. SJ Moschos HD Edington SR Land, et al. 2006 Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 19 3164 3171 1:CAS:528: DC%2BD28XnslKhsL0%3D 16809739
20. Knecht R, Peters S, Solbach C, Baghi M, Gstottner W, Hambek M (2003) EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Anticancer Res 23(6C):4789-4795
21. S Tanaka A Tatsuguchi S Futagami, et al. 2006 Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma Gut 55 1 54 61 1:CAS:528:DC%2BD28Xnt1yqtw%3D%3D 16085694
22. K Oba S Teramukai M Kobayashi T Matsui Y Kodera J Sakamoto 2007 Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer Cancer Immunol Immunother 56 6 905 911 1:CAS:528:DC%2BD2sXjsFyhtbg%3D 17106715
23. H Kumazawa T Yamashita T Tachikawa M Minamino Y Nakata 1994 Local injection of OK-432/fibrinogen gel into head and neck carcinomas Eur J Cancer 30A 12 1741 1744 1:STN:280:DyaK2M7os1ahtQ%3D%3D 7880597
24. K Naito Y Ueda T Itoh, et al. 2006 Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity Int J Oncol 28 6 1481 1489 1:CAS:528:DC%2BD28XlvVOhsrw%3D 16685449
25. Elojeimy S, McKillop JC, El-Zawahry AM et al (2006) FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 13(8):739-745
26. FM Burnet 1970 The concept of immunological surveillance Prog Exp Tumor Res 13 1 27 1:STN:280:DyaE3M%2FjvFektg%3D%3D 4921480
27. RJ De Boer P Hogeweg 1985 Tumor escape from immune elimination: simplified precursor bound cytotoxicity models J Theor Biol 113 4 719 736 3875757
28. JD Kerrebijn AJ Balm JL Freeman HM Dosch HA Drexhage 1999 Who is in control of the immune system in head and neck cancer? Crit Rev Oncol Hematol 31 1 31 53 1:STN:280:DC%2BD3c%2FgtFWqug%3D%3D 10532189
29. I Hellstrom KE Hellstrom 1983 Cell-mediated reactivity to human tumor-type associated antigens: does it exist? J Biol Response Mod 2 4 310 320 1:STN:280:DyaL2c%2FmtlOmtA%3D%3D 6358420
30. JW Pollard 2004 Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 1 71 78 1:CAS:528:DC%2BD2cXos12qtA%3D%3D 14708027
31. E Gorelik Y Gunji RH Goldfarb 1988 Interaction of tumor cells and immune system in the metastatic process Biochem Cell Biol 66 6 617 625 1:CAS:528:DyaL1cXkvFSrsrg%3D 3048334
32. FR Miller 1993 Immune mechanisms in the sequential steps of metastasis Crit Rev Oncog 4 3 293 311 1:CAS:528:DyaK3sXitlWksLY%3D 7683497
33. KJ Malmberg HG Ljunggren 2006 Escape from immune- and nonimmune-mediated tumor surveillance Semin Cancer Biol 16 1 16 31 1:CAS:528:DC%2BD28XotVCmtw%3D%3D 16140546
34. C Lamagna M Aurrand-Lions BA Imhof 2006 Dual role of macrophages in tumor growth and angiogenesis J Leukoc Biol 80 4 705 713 1:CAS:528:DC%2BD28XhtV2hsLzO 16864600
35. S Rakoff-Nahoum 2006 Why cancer and inflammation? Yale J Biol Med 79 3-4 123 130 1:CAS:528:DC%2BD1cXisFKgtr8%3D 17940622
36. SK Bunt L Yang P Sinha VK Clements J Leips S Ostrand-Rosenberg 2007 Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression Cancer Res 67 20 10019 10026 1:CAS:528:DC%2BD2sXhtFOnsLrF 17942936
37. HC Hafkamp JJ Manni EJ Speel 2004 Role of human papillomavirus in the development of head and neck squamous cell carcinomas Acta Otolaryngol 124 4 520 526 15224887
38. SK Bunt P Sinha VK Clements J Leips S Ostrand-Rosenberg 2006 Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression J Immunol 176 1 284 290 1:CAS:528:DC%2BD2MXhtlagtL7I 16365420
39. E Burstein ER Fearon 2008 Colitis and cancer: a tale of inflammatory cells and their cytokines J Clin Invest 118 2 464 467 1:CAS:528: DC%2BD1cXhsFOnu7w%3D 18219390
40. MS Hayden AP West S Ghosh 2006 NF-kappaB and the immune response Oncogene 25 51 6758 6780 1:CAS:528:DC%2BD28XhtFektL7P 17072327
41. CT Allen JL Ricker Z Chen C Van Waes 2007 Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck Head Neck 29 10 959 971 17405170
42. F Wang P Arun J Friedman Z Chen C Van Waes 2009 Current and potential inflammation targeted therapies in head and neck cancer Curr Opin Pharmacol 9 4 389 395 1:CAS:528:DC%2BD1MXhtVenurnE 19570715
43. JH Heimdal HJ Aarstad B Klementsen J Olofsson 1998 Disease stage related in vitro responsiveness of peripheral blood T-lymphocytes in patients with head and neck carcinoma Acta Otolaryngol 118 6 887 891 1:STN:280: DyaK1M%2Fos1WrtA%3D%3D 9870639
44. Vlock DR (1991) Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates. Hematol Oncol Clin North Am 5(4):797-820
45. K Chikamatsu K Sakakura TL Whiteside N Furuya 2007 Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck Head Neck 29 2 120 127 17103408
46. HJ Aarstad JH Heimdal B Klementsen J Olofsson E Ulvestad 2006 Presence of activated T lymphocytes in peripheral blood of head and neck squamous cell carcinoma patients predicts impaired prognosis Acta Otolaryngol 126 12 1326 1333 17101596
47. TL Whiteside 2005 Immunobiology of head and neck cancer Cancer Metastasis Rev 24 1 95 105 1:CAS:528:DC%2BD2MXisV2kt7s%3D 15785875
48. RB Johnston Jr 1988 Current concepts: immunology. Monocytes and macrophages N Engl J Med 318 12 747 752 3279314
49. R Seljelid 1987 Effector functions of macrophages Acta Med Scand Suppl 715 131 138 1:CAS:528:DyaL2sXkslGlt7g%3D 3109213
50. R Seljelid T Eskeland 1993 The biology of macrophages: I. General principles and properties Eur J Haematol 51 5 267 275 1:STN:280: DyaK2c7gvFGlsw%3D%3D 8282087
51. DT Fearon RM Locksley 1996 The instructive role of innate immunity in the acquired immune response Science 272 5258 50 53 1:CAS:528:DyaK28XitVKkt78%3D 8600536
52. Burke B, Lewis CE (2002) The macrophage. 2nd edn. Oxford University Press, New York
53. Vuk-Pavlovic S (2007) Rebuilding immunity in cancer patients. Blood Cells Mol Dis 40(1):94-100
54. S Kusmartsev DI Gabrilovich 2006 Role of immature myeloid cells in mechanisms of immune evasion in cancer Cancer Immunol Immunother 55 3 237 245 16047143
55. O Gallo AM Gori M Attanasio, et al. 1993 Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer Br J Cancer 68 3 465 468 1:STN:280:DyaK3szlslWgug%3D%3D 8353036
56. JH Heimdal HJ Aarstad B Klementsen J Olofsson 1999 Ex vivo interleukin (IL)-1 beta, IL-6, IL-12 and tumor necrosis factor-alpha responsiveness with monocytes from patients with head and neck carcinoma Eur Arch Otorhinolaryngol 256 5 250 256 1:STN:280:DyaK1MzitVGqug%3D%3D 10392301
57. B Mytar M Woloszyn R Szatanek, et al. 2003 Tumor cell-induced deactivation of human monocytes J Leukoc Biol 74 6 1094 1101 1:CAS:528:DC%2BD3sXpvFejt7o%3D 12960282
58. Z Chen PS Malhotra GR Thomas, et al. 1999 Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer Clin Cancer Res 5 6 1369 1379 1:STN:280:DyaK1Mzhs1OrsQ%3D%3D 10389921
59. SK Watkins NK Egilmez J Suttles RD Stout 2007 IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo J Immunol 178 3 1357 1362 1:CAS:528:DC%2BD2sXntVGhsg%3D%3D 17237382
60. R Valenti V Huber M Iero P Filipazzi G Parmiani L Rivoltini 2007 Tumor-released microvesicles as vehicles of immunosuppression Cancer Res 67 7 2912 2915 1:CAS:528:DC%2BD2sXksVGlt7o%3D 17409393
61. C Li S Shintani N Terakado K Nakashiro H Hamakawa 2002 Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma Oncol Rep 9 6 1219 1223 12375023
62. C Liss MJ Fekete R Hasina CD Lam MW Lingen 2001 Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages Int J Cancer 93 6 781 785 1:CAS:528:DC%2BD3MXlvF2mtbw%3D 11519037
63. Johansson M, Tan T, de Visser KE, Coussens LM (2007) Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem 101(4):918-926
64. KW Kross JH Heimdal C Olsnes J Olofsson HJ Aarstad 2005 Head and neck squamous cell carcinoma spheroid- and monocyte spheroid-stimulated IL-6 and monocyte chemotactic protein-1 secretion are related to TNM stage, inflammatory state and tumor macrophage density Acta Otolaryngol 125 10 1097 1104 1:CAS:528:DC%2BD2MXhtV2htLbF 16298793
65. M Ohta Y Kitadai S Tanaka, et al. 2002 Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas Int J Cancer 102 3 220 224 1:CAS:528:DC%2BD38Xotlait7k%3D 12397639
66. B Marcus D Arenberg J Lee, et al. 2004 Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma Cancer 101 12 2779 2787 15546137
67. A Mantovani P Allavena A Sica 2004 Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression Eur J Cancer 40 11 1660 1667 1:CAS:528:DC%2BD2cXls1Wntr4%3D 15251154
68. T Ueno M Toi H Saji, et al. 2000 Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clin Cancer Res 6 8 3282 3289 1:CAS:528: DC%2BD3cXmsVOmt7c%3D 10955814
69. Y Nakayama N Nagashima N Minagawa, et al. 2002 Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer Anticancer Res 22 6C 4291 4296 12553072
70. K Kleine-Lowinski R Gillitzer R Kuhne-Heid F Rosl 1999 Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas Int J Cancer 82 1 6 11 1:STN:280:DyaK1M3oslGmtQ%3D%3D 10360812
71. RD Leek AL Harris 2002 Tumor-associated macrophages in breast cancer J Mammary Gland Biol Neoplasia 7 2 177 189 12463738
72. T Valkovic D Fuckar S Stifter, et al. 2005 Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma J Cancer Res Clin Oncol 131 7 453 458 1:CAS:528:DC%2BD2MXmvVaksbc%3D 15883814
73. ML Varney SL Johansson RK Singh 2005 Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A Melanoma Res 15 5 417 425 1:CAS:528:DC%2BD2MXhtVantb3F 16179869
74. A Sica T Schioppa A Mantovani P Allavena 2006 Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy Eur J Cancer 42 6 717 727 1:CAS:528:DC%2BD28Xjs1Grt78%3D 16520032
75. RD Stout J Suttles 2004 Functional plasticity of macrophages: reversible adaptation to changing microenvironments J Leukoc Biol 76 3 509 513 1:CAS:528:DC%2BD2cXnsVaksrg%3D 15218057
76. E Kontny M Ziolkowska A Ryzewska W Maslinski 1999 Protein kinase c-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) Cytokine 11 11 839 848 1:CAS:528:DyaK1MXntVahtLY%3D 10547271 (Pubitemid 29537532)
77. DR Hodge EM Hurt WL Farrar 2005 The role of IL-6 and STAT3 in inflammation and cancer Eur J Cancer 41 16 2502 2512 1:CAS:528: DC%2BD2MXhtFyks73E 16199153
78. D Kamimura K Ishihara T Hirano 2003 IL-6 signal transduction and its physiological roles: the signal orchestration model Rev Physiol Biochem Pharmacol 149 1 38 1:CAS:528:DC%2BD2cXitFSluro%3D 12687404
79. V Sriuranpong JI Park P Amornphimoltham V Patel BD Nelkin JS Gutkind 2003 Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system Cancer Res 63 11 2948 2956 1:CAS:528:DC%2BD3sXkt1ait7Y%3D 12782602
80. T Bowman R Garcia J Turkson R Jove 2000 STATs in oncogenesis Oncogene 19 21 2474 2488 1:CAS:528:DC%2BD3cXktVGhsb8%3D 10851046
81. JR Grandis SD Drenning Q Zeng, et al. 2000 Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo Proc Natl Acad Sci USA 97 8 4227 4232 1:CAS:528:DC%2BD3cXislSgu7o%3D 10760290
82. T Kanazawa H Nishino M Hasegawa, et al. 2007 Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells Eur Arch Otorhinolaryngol 264 7 815 821 17310346
83. H Nishino M Miyata K Kitamura 1998 The effect of interleukin-6 on enhancing the invasiveness of head and neck cancer cells in vitro Eur Arch Otorhinolaryngol 255 9 468 472 1:STN:280:DyaK1M%2FltVCisg%3D%3D 9833216
84. DD Taub P Proost WJ Murphy, et al. 1995 Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes J Clin Invest 95 3 1370 1376 1:CAS:528:DyaK2MXktlKgsr0%3D 7883984
85. P Allavena G Bianchi D Zhou, et al. 1994 Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3 Eur J Immunol 24 12 3233 3236 1:CAS:528:DyaK2MXislWnsLg%3D 7805752
86. EJ Leonard A Skeel T Yoshimura J Rankin 1993 Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes Adv Exp Med Biol 351 55 64 1:CAS:528:DyaK2cXmsFeis7c%3D 7942299
87. T Yoshimura EA Robinson S Tanaka E Appella J Kuratsu EJ Leonard 1989 Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants J Exp Med 169 4 1449 1459 1:CAS:528:DyaL1MXhvFShs70%3D 2926329
88. I Conti BJ Rollins 2004 CCL2 (monocyte chemoattractant protein-1) and cancer Semin Cancer Biol 14 3 149 154 1:CAS:528:DC%2BD2cXjvVemsb4%3D 15246049
89. B Huang Z Lei J Zhao, et al. 2007 CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers Cancer Lett 252 1 86 92 1:CAS:528:DC%2BD2sXlsF2ksLs%3D 17257744
90. C Bailey R Negus A Morris, et al. 2007 Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer Clin Exp Metastasis 24 2 121 130 1:CAS:528: DC%2BD2sXmt1Cqsbc%3D 17390111
91. MH Bemelmans LJ van Tits WA Buurman 1996 Tumor necrosis factor: function, release and clearance Crit Rev Immunol 16 1 1 11 1:CAS:528:DyaK28XkvV2iu7s%3D 8809470
92. JR Bradley 2008 TNF-mediated inflammatory disease J Pathol 214 2 149 160 1:CAS:528:DC%2BD1cXhvFCktrY%3D 18161752
93. R Kumar PE Herbert AN Warrens 2005 An introduction to death receptors in apoptosis Int J Surg 3 4 268 277 1:STN:280:DC%2BD2s3ltlCitw%3D%3D 17462297
94. J Yao N Mackman TS Edgington ST Fan 1997 Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors J Biol Chem 272 28 17795 17801 1:CAS:528:DyaK2sXksFyjsL8%3D 9211933
95. JH Heimdal K Kross B Klementsen J Olofsson HJ Aarstad 2008 Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma BMC Cancer 8 34 18234094
96. KW Kross JH Heimdal C Olsnes J Olofsson HJ Aarstad 2008 Co-culture of head and neck squamous cell carcinoma spheroids with autologous monocytes predicts prognosis Scand J Immunol 67 4 392 399 1:CAS:528:DC%2BD1cXkslKru7s%3D 18282234
97. SA Duffy JM Taylor JE Terrell, et al. 2008 Interleukin-6 predicts recurrence and survival among head and neck cancer patients Cancer 113 4 750 757 18536030
98. PK Ha JA Califano 2003 The molecular biology of mucosal field cancerization of the head and neck Crit Rev Oral Biol Med 14 5 363 369 14530304
99. H De Schutter W Landuyt E Verbeken L Goethals R Hermans S Nuyts 2005 The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy BMC Cancer 5 1 42 15847702
100. R Pries B Wollenberg 2006 Cytokines in head and neck cancer Cytokine Growth Factor Rev 17 3 141 146 1:CAS:528:DC%2BD28Xltleltrk%3D 16540364
101. F Riedel I Zaiss D Herzog K Gotte R Naim K Hormann 2005 Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma Anticancer Res 25 4 2761 2765 1:CAS:528:DC%2BD2MXpt1Wrsrs%3D 16080523
102. AD Rapidis GT Wolf 2009 Immunotherapy of head and neck cancer: current and future considerations J Oncol 2009 346345 19680453
103. RC Ward HL Kaufman 2007 Targeting costimulatory pathways for tumor immunotherapy Int Rev Immunol 26 3-4 161 196 1:CAS:528:DC%2BD2sXmt1agur4%3D 17558743
104. TL Whiteside NL Vujanovic RB Herberman 1998 Natural killer cells and tumor therapy Curr Top Microbiol Immunol 230 221 244 1:CAS:528: DyaK1cXjt1ymt7c%3D 9586358
105. MS Leibowitz JV Nayak RL Ferris 2008 Head and neck cancer immunotherapy: clinical evaluation Curr Oncol Rep 10 2 162 169 1:CAS:528:DC%2BD1cXktVOjsrY%3D 18377830
106. HG Ljunggren KJ Malmberg 2007 Prospects for the use of NK cells in immunotherapy of human cancer Nat Rev Immunol 7 5 329 339 1:CAS:528: DC%2BD2sXksFeks74%3D 17438573
107. DS Hong LS Angelo R Kurzrock 2007 Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 110 9 1911 1928 1:CAS:528:DC%2BD2sXhtlertbrN 17849470